| Year |
Citation |
Score |
| 2016 |
Mavrou A, Oltean S. SRPK1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of VEGF alternative splicing. Pharmacological Research. PMID 26995304 DOI: 10.1016/J.Phrs.2016.03.013 |
0.444 |
|
| 2014 |
Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene. PMID 25381816 DOI: 10.1038/Onc.2014.360 |
0.707 |
|
| 2014 |
Mavrou A, Bates D, Oltean S. Abstract 2749: SRPK1 inhibition and modulation of VEGF alternative splicing as a potential therapeutic strategy in prostate cancer Cancer Research. 74: 2749-2749. DOI: 10.1158/1538-7445.Am2014-2749 |
0.5 |
|
| 2013 |
Bates DO, Mavrou A, Qiu Y, Carter JG, Hamdollah-Zadeh M, Barratt S, Gammons MV, Millar AB, Salmon AH, Oltean S, Harper SJ. Detection of VEGF-A(xxx)b isoforms in human tissues. Plos One. 8: e68399. PMID 23935865 DOI: 10.1371/Journal.Pone.0068399 |
0.507 |
|
| 2013 |
Mavrou A, Oltean S, Bates D. Abstract 380: Serine-Arginine protein kinase 1 (SRPK1) - A potential target of angiogenesis in prostate cancer. Cancer Research. 73: 380-380. DOI: 10.1158/1538-7445.Am2013-380 |
0.575 |
|
| 2012 |
Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR, Bates DO. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochemical Society Transactions. 40: 831-5. PMID 22817743 DOI: 10.1042/Bst20120051 |
0.624 |
|
| 2012 |
Oltean S, Neal CR, Mavrou A, Patel P, Ahad T, Alsop C, Lee T, Sison K, Qiu Y, Harper SJ, Bates DO, Salmon AH. VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice. American Journal of Physiology. Renal Physiology. 303: F1026-36. PMID 22811490 DOI: 10.1152/Ajprenal.00410.2011 |
0.739 |
|
| Show low-probability matches. |